| Withdrawn | TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer NCT02070419 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Ca NCT02088775 | Fox Chase Cancer Center | N/A |
| Active Not Recruiting | Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT NCT02119065 | University of Cincinnati | — |
| Completed | CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery NCT01766219 | Wake Forest University Health Sciences | Phase 1 / Phase 2 |
| Completed | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer NCT01730937 | Radiation Therapy Oncology Group | Phase 3 |
| Withdrawn | Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duc NCT01859182 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer NCT01624285 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery NCT02072356 | Ohio State University Comprehensive Cancer Center | EARLY_Phase 1 |
| Terminated | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers NCT01229111 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant NCT01194206 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer NCT00427973 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant NCT00844168 | University of Washington | Phase 1 |
| Terminated | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer NCT00787787 | University of Washington | Phase 2 |
| Completed | IMC-A12 in Treating Patients With Advanced Liver Cancer NCT00639509 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer NCT00604721 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery NCT00459108 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer NCT00365391 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery NCT00321594 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer NCT00107536 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) NCT00077441 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot B NCT00101036 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | Doxorubicin and Bortezomib in Treating Patients With Liver Cancer NCT00083226 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) NCT00071994 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Du NCT00085410 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer NCT00055692 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oxaliplatin in Treating Patients With Liver Cancer NCT00052364 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction NCT00047346 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer NCT00033462 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | BMS-247550 in Treating Patients With Liver or Gallbladder Cancer NCT00023946 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |